vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Oil-Dri Corp of America (ODC). Click either name above to swap in a different company.

Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $120.5M, roughly 1.4× Oil-Dri Corp of America). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -5.8%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 6.8%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Oil-Dri Corporation of America is a leading manufacturer and marketer of specialty sorbent and clay-based products. Its offerings include industrial spill cleanup absorbents, pet care goods such as cat litter, agricultural soil amendments, and sports field conditioning materials, serving customers across North America and other global commercial markets.

ESPR vs ODC — Head-to-Head

Bigger by revenue
ESPR
ESPR
1.4× larger
ESPR
$168.4M
$120.5M
ODC
Growing faster (revenue YoY)
ESPR
ESPR
+149.6% gap
ESPR
143.7%
-5.8%
ODC
Faster 2-yr revenue CAGR
ESPR
ESPR
Annualised
ESPR
10.6%
6.8%
ODC

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ESPR
ESPR
ODC
ODC
Revenue
$168.4M
$120.5M
Net Profit
$15.5M
Gross Margin
29.5%
Operating Margin
50.6%
14.1%
Net Margin
12.8%
Revenue YoY
143.7%
-5.8%
Net Profit YoY
-5.6%
EPS (diluted)
$0.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
ODC
ODC
Q4 25
$168.4M
$120.5M
Q3 25
$87.3M
$125.2M
Q2 25
$82.4M
$115.5M
Q1 25
$65.0M
$116.9M
Q4 24
$69.1M
$127.9M
Q3 24
$51.6M
$113.7M
Q2 24
$73.8M
$106.8M
Q1 24
$137.7M
$105.7M
Net Profit
ESPR
ESPR
ODC
ODC
Q4 25
$15.5M
Q3 25
$-31.3M
$13.1M
Q2 25
$-12.7M
$11.6M
Q1 25
$-40.5M
$12.9M
Q4 24
$16.4M
Q3 24
$-29.5M
$8.5M
Q2 24
$-61.9M
$7.8M
Q1 24
$61.0M
$12.4M
Gross Margin
ESPR
ESPR
ODC
ODC
Q4 25
29.5%
Q3 25
27.8%
Q2 25
28.6%
Q1 25
29.5%
Q4 24
31.9%
Q3 24
29.0%
Q2 24
28.2%
Q1 24
29.3%
Operating Margin
ESPR
ESPR
ODC
ODC
Q4 25
50.6%
14.1%
Q3 25
-11.4%
12.5%
Q2 25
8.6%
12.0%
Q1 25
-34.0%
15.0%
Q4 24
-6.4%
16.6%
Q3 24
-31.0%
11.3%
Q2 24
3.5%
9.8%
Q1 24
52.5%
14.4%
Net Margin
ESPR
ESPR
ODC
ODC
Q4 25
12.8%
Q3 25
-35.9%
10.4%
Q2 25
-15.4%
10.1%
Q1 25
-62.2%
11.1%
Q4 24
12.8%
Q3 24
-57.2%
7.5%
Q2 24
-83.9%
7.3%
Q1 24
44.3%
11.7%
EPS (diluted)
ESPR
ESPR
ODC
ODC
Q4 25
$0.32
Q3 25
$-0.16
Q2 25
$-0.06
Q1 25
$-0.21
Q4 24
$-0.14
Q3 24
$-0.15
Q2 24
$-0.33
Q1 24
$0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
ODC
ODC
Cash + ST InvestmentsLiquidity on hand
$167.9M
$42.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$-302.0M
$266.5M
Total Assets
$465.9M
$380.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
ODC
ODC
Q4 25
$167.9M
$42.4M
Q3 25
$92.4M
$50.5M
Q2 25
$86.1M
$36.5M
Q1 25
$114.6M
$22.6M
Q4 24
$144.8M
$12.5M
Q3 24
$144.7M
$23.5M
Q2 24
$189.3M
$46.8M
Q1 24
$226.6M
$27.8M
Stockholders' Equity
ESPR
ESPR
ODC
ODC
Q4 25
$-302.0M
$266.5M
Q3 25
$-451.4M
$259.1M
Q2 25
$-433.5M
$246.9M
Q1 25
$-426.2M
$235.9M
Q4 24
$-388.7M
$224.0M
Q3 24
$-370.2M
$210.6M
Q2 24
$-344.2M
$202.9M
Q1 24
$-294.3M
$196.0M
Total Assets
ESPR
ESPR
ODC
ODC
Q4 25
$465.9M
$380.7M
Q3 25
$364.0M
$391.7M
Q2 25
$347.1M
$369.5M
Q1 25
$324.0M
$353.7M
Q4 24
$343.8M
$350.2M
Q3 24
$314.1M
$354.6M
Q2 24
$352.3M
$319.2M
Q1 24
$373.1M
$296.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
ODC
ODC
Operating Cash FlowLast quarter
$45.2M
$10.3M
Free Cash FlowOCF − Capex
$1.3M
FCF MarginFCF / Revenue
1.1%
Capex IntensityCapex / Revenue
0.0%
7.5%
Cash ConversionOCF / Net Profit
0.67×
TTM Free Cash FlowTrailing 4 quarters
$50.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
ODC
ODC
Q4 25
$45.2M
$10.3M
Q3 25
$-4.3M
$25.2M
Q2 25
$-31.4M
$22.7M
Q1 25
$-22.6M
$21.4M
Q4 24
$-35.0M
$10.9M
Q3 24
$-35.3M
$23.4M
Q2 24
$-7.2M
$19.0M
Q1 24
$53.8M
$9.4M
Free Cash Flow
ESPR
ESPR
ODC
ODC
Q4 25
$1.3M
Q3 25
$17.1M
Q2 25
$16.0M
Q1 25
$16.4M
Q4 24
$-1.9M
Q3 24
$-35.5M
$15.1M
Q2 24
$-7.3M
$10.8M
Q1 24
$53.8M
$1.9M
FCF Margin
ESPR
ESPR
ODC
ODC
Q4 25
1.1%
Q3 25
13.7%
Q2 25
13.8%
Q1 25
14.0%
Q4 24
-1.5%
Q3 24
-68.7%
13.3%
Q2 24
-9.9%
10.1%
Q1 24
39.0%
1.8%
Capex Intensity
ESPR
ESPR
ODC
ODC
Q4 25
0.0%
7.5%
Q3 25
0.0%
6.5%
Q2 25
0.0%
5.8%
Q1 25
0.0%
4.3%
Q4 24
0.0%
10.0%
Q3 24
0.3%
7.3%
Q2 24
0.1%
7.7%
Q1 24
0.1%
7.1%
Cash Conversion
ESPR
ESPR
ODC
ODC
Q4 25
0.67×
Q3 25
1.93×
Q2 25
1.95×
Q1 25
1.66×
Q4 24
0.67×
Q3 24
2.74×
Q2 24
2.44×
Q1 24
0.88×
0.76×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

ODC
ODC

Cat Litter$64.6M54%
Fluids Purification$26.7M22%
Agriculturaland Horticultural$12.9M11%
Industrialand Sports$11.6M10%
Animal Healthand Nutrition$4.7M4%

Related Comparisons